NO20081574L - Anvendelse av IL-23- og IL-17-antagonister for behandling av autoimmun, okulaer, inflammatorisk sykdom - Google Patents

Anvendelse av IL-23- og IL-17-antagonister for behandling av autoimmun, okulaer, inflammatorisk sykdom

Info

Publication number
NO20081574L
NO20081574L NO20081574A NO20081574A NO20081574L NO 20081574 L NO20081574 L NO 20081574L NO 20081574 A NO20081574 A NO 20081574A NO 20081574 A NO20081574 A NO 20081574A NO 20081574 L NO20081574 L NO 20081574L
Authority
NO
Norway
Prior art keywords
inflammatory disease
ocular
autoimmune
antagonists
treatment
Prior art date
Application number
NO20081574A
Other languages
English (en)
Norwegian (no)
Inventor
Robert A Kastelein
Daniel J Cua
Van T Tsai
Rachel Casp
Phyllis Silver
Dror Luger
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081574(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of NO20081574L publication Critical patent/NO20081574L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20081574A 2005-09-01 2008-03-31 Anvendelse av IL-23- og IL-17-antagonister for behandling av autoimmun, okulaer, inflammatorisk sykdom NO20081574L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71379205P 2005-09-01 2005-09-01
US83731206P 2006-08-11 2006-08-11
PCT/US2006/033840 WO2007027761A2 (en) 2005-09-01 2006-08-30 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Publications (1)

Publication Number Publication Date
NO20081574L true NO20081574L (no) 2008-05-30

Family

ID=37686002

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081574A NO20081574L (no) 2005-09-01 2008-03-31 Anvendelse av IL-23- og IL-17-antagonister for behandling av autoimmun, okulaer, inflammatorisk sykdom

Country Status (21)

Country Link
US (6) US20080199460A1 (enExample)
EP (3) EP2322219A3 (enExample)
JP (3) JP2009507023A (enExample)
CN (1) CN101296706B (enExample)
AT (1) ATE445415T1 (enExample)
AU (1) AU2006284841B2 (enExample)
BR (1) BRPI0615297A2 (enExample)
CA (1) CA2621086A1 (enExample)
CY (1) CY1110606T1 (enExample)
DE (1) DE602006009834D1 (enExample)
DK (1) DK1933869T3 (enExample)
ES (1) ES2333260T3 (enExample)
HR (1) HRP20100014T1 (enExample)
NO (1) NO20081574L (enExample)
NZ (2) NZ595262A (enExample)
PL (1) PL1933869T3 (enExample)
PT (1) PT1933869E (enExample)
RS (1) RS51142B (enExample)
SI (1) SI1933869T1 (enExample)
TW (2) TWI372061B (enExample)
WO (1) WO2007027761A2 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
AU2006342792A1 (en) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CA2679400A1 (en) * 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
ES2465223T3 (es) * 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
EP3246045B1 (en) * 2007-07-26 2025-09-03 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
WO2009023267A2 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Methods for modulating development and expansion of il-17 expressing cells
WO2009068631A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
AU2009204441B2 (en) 2008-01-09 2015-03-05 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
CN104151428B (zh) * 2008-02-21 2017-07-14 麒麟-安姆根有限公司 Il‑17ra‑il‑17rb拮抗物及其用途
CA2721713C (en) 2008-05-05 2019-07-09 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
AU2010203425B2 (en) 2009-01-09 2015-04-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
SG174891A1 (en) * 2009-04-01 2011-11-28 Genentech Inc Treatment of insulin-resistant disorders
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
US9301997B2 (en) 2009-09-21 2016-04-05 Peptinov Sas Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
SI3295957T1 (sl) 2010-01-15 2020-02-28 Kirin-Amgen, Inc. Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
SG187231A1 (en) 2010-07-29 2013-02-28 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
RU2665954C1 (ru) * 2010-10-08 2018-09-05 Новартис Аг Способы лечения псориаза с использованием антагонистов il-17
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US20140314798A1 (en) * 2011-10-21 2014-10-23 Baylor College Of Medicine Method to measure inflammation in the conjunctiva of patients with tear dysfunction
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
CA2868404A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
CN104507497B (zh) 2012-05-03 2018-10-19 勃林格殷格翰国际有限公司 抗IL-23p19抗体
ES2711554T3 (es) 2012-05-22 2019-05-06 Bristol Myers Squibb Co Anticuerpos biespecíficos contra IL-17A/F IL-23 y sus usos
EP2931311A4 (en) * 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
WO2014107737A2 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
CN107693781B (zh) 2013-03-13 2021-11-09 巴扎德制药公司 用于眼部递送的嵌合细胞因子制剂
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
AR101753A1 (es) 2014-09-03 2017-01-11 Boehringer Ingelheim Int COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
PL3065748T3 (pl) 2014-12-23 2018-07-31 4D Pharma Research Limited Szczep Bacteroides thetaiotaomicron i jego zastosowanie w zmniejszaniu zapalenia
KR20170091157A (ko) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 피린 폴리펩티드 및 면역 조정
EP3242714B1 (en) 2014-12-31 2021-06-02 Stimwave Technologies Incorporated Antenna assembly
WO2016123329A2 (en) * 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
SG10202103879YA (en) 2015-02-04 2021-05-28 Boehringer Ingelheim Int Methods of treating inflammatory diseases
CN104725514A (zh) * 2015-02-06 2015-06-24 中国药科大学 新型il23拮抗剂
EA201890050A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MD3650033T2 (ro) 2015-06-15 2022-08-31 4D Pharma Res Ltd Compoziții conţinând tulpini bacteriene
SI3240554T1 (sl) 2015-06-15 2019-12-31 4D Pharma Research Limited, Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
HK1258292A1 (zh) 2015-09-17 2019-11-08 Amgen Inc. 使用il23途径生物标志物预测il23拮抗剂的临床应答
AU2016357554B2 (en) 2015-11-20 2019-04-04 Cj Bioscience, Inc. Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
MD3804737T2 (ro) 2017-06-14 2022-10-31 4D Pharma Res Limited Compoziții care conțin tulpini bacteriene
CN115813955A (zh) 2017-06-14 2023-03-21 4D制药研究有限公司 包含细菌菌株的组合物
TW202123965A (zh) 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
JP7819178B2 (ja) 2020-08-05 2026-02-24 シンセカイン インコーポレイテッド ＩＬ１０Ｒｂ結合分子および使用方法
US12077594B2 (en) 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
WO2022031870A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. IL27Rα BINDING MOLECULES AND METHODS OF USE
EP4192880A4 (en) 2020-08-05 2025-04-30 Synthekine, Inc. IL10 receptor-binding molecules and methods of use
US12012457B1 (en) 2020-08-05 2024-06-18 Synthekine, Inc. IL23R binding molecules and methods of use
US12291572B2 (en) 2020-08-05 2025-05-06 Synthekine, Inc. IL12 receptor synthetic cytokines and methods of use
CN116323669A (zh) * 2020-08-05 2023-06-23 辛德凯因股份有限公司 受体配对相关的组合物和方法
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
BR112023001723A2 (pt) 2020-08-05 2023-05-02 Synthekine Inc Moléculas de ligação à gp130 e métodos de uso
CN116829585A (zh) 2020-08-05 2023-09-29 辛德凯因股份有限公司 Il27受体结合相关的组合物和方法
US12234291B2 (en) 2020-08-05 2025-02-25 Synthekine, Inc. IL2RB binding molecules and methods of use
WO2022031885A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10ra binding molecules and methods of use
KR20240082379A (ko) * 2021-10-03 2024-06-10 시스트이뮨, 인코포레이티드 암 치료 방법 및 이의 약제학적 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
MX9707021A (es) 1995-03-23 1997-11-29 Immunex Corp Receptor de il-7.
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
WO2002008285A2 (en) 2000-06-22 2002-01-31 Amgen, Inc. Il-17 molecules and uses thereof
WO2002097048A2 (en) 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2005010044A2 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
EP1576011B1 (en) * 2002-10-30 2009-08-12 Genentech, Inc. Inhibition of il-17 production
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
ATE440864T1 (de) 2003-03-10 2009-09-15 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
JP2007515939A (ja) * 2003-05-09 2007-06-21 セントカー・インコーポレーテツド ＩＬ−２３ｐ４０特異的免疫グロブリン由来タンパク質、組成物、方法および用途
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
AU2005241020B2 (en) * 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
EP1766396B1 (en) 2004-06-07 2010-08-11 Ramot at Tel-Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
JP2008505080A (ja) * 2004-07-01 2008-02-21 ニューヨーク ユニバーシティー ＲＯＲγｔ機能の調節のための組成物および方法
DE102005032499B4 (de) * 2004-07-13 2009-10-22 Lg Electronics Inc. Dämpfer zur Vibrationsdämpfung und damit ausgerüstete Waschmaschine
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
WO2006060194A1 (en) * 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
CA2588449A1 (en) 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
TWI363091B (en) * 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
EA016022B1 (ru) 2004-12-21 2012-01-30 Сентокор, Инк. Выделенное антитело млекопитающего против il-12 и способ изменения его активности
EP2322553A3 (en) * 2005-02-14 2011-11-16 Wyeth LLC Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
CN103146708A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
EP2452694B1 (en) * 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
LT1931710T (lt) 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
RS55963B1 (sr) 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds

Also Published As

Publication number Publication date
ATE445415T1 (de) 2009-10-15
CY1110606T1 (el) 2015-04-29
US20130323251A1 (en) 2013-12-05
JP2009507023A (ja) 2009-02-19
JP5462838B2 (ja) 2014-04-02
NZ595262A (en) 2013-03-28
US20110142831A1 (en) 2011-06-16
CA2621086A1 (en) 2007-03-08
CN101296706A (zh) 2008-10-29
BRPI0615297A2 (pt) 2011-05-17
DK1933869T3 (da) 2010-03-01
US20100111950A1 (en) 2010-05-06
EP1933869B1 (en) 2009-10-14
AU2006284841B2 (en) 2012-11-08
JP2014005285A (ja) 2014-01-16
EP2322219A2 (en) 2011-05-18
TW201235050A (en) 2012-09-01
US8524230B2 (en) 2013-09-03
NZ566424A (en) 2011-10-28
DE602006009834D1 (de) 2009-11-26
EP2322219A3 (en) 2013-06-05
HK1119578A1 (en) 2009-03-13
EP1933869A2 (en) 2008-06-25
PT1933869E (pt) 2009-12-24
WO2007027761A2 (en) 2007-03-08
TWI372061B (en) 2012-09-11
US20100111954A1 (en) 2010-05-06
WO2007027761A3 (en) 2007-05-03
HRP20100014T1 (hr) 2010-02-28
TW200800259A (en) 2008-01-01
PL1933869T3 (pl) 2010-06-30
JP2011184466A (ja) 2011-09-22
RS51142B (sr) 2010-10-31
TWI463993B (zh) 2014-12-11
CN101296706B (zh) 2011-11-30
ES2333260T3 (es) 2010-02-18
EP2116258A1 (en) 2009-11-11
US20140248279A1 (en) 2014-09-04
US20080199460A1 (en) 2008-08-21
AU2006284841A1 (en) 2007-03-08
SI1933869T1 (sl) 2010-02-26

Similar Documents

Publication Publication Date Title
DK1933869T3 (da) Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom
NL301089I2 (nl) imlifidase
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
NL1026329A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
WO2007022506A3 (en) Methods and compositions for treating neurological disease
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
NL1026327A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
NL1028087A1 (nl) Sulfonamiderivaten voor de behandeling van ziekten.
NO20053384D0 (no) Benzazepinderivater for behandling av neurologiske forstyrrelser.
WO2006002437A3 (en) Treatment of conditions involving demyelination
NO20064896L (no) Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer
EA200800342A1 (ru) ИНГИБИТОРЫ Glepp-1 ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И/ИЛИ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
NL1028597A1 (nl) Formamidederivaten voor de behandeling van ziekten.
WO2007031329A3 (de) Verwendung eines kollagens xenogenen ursprungs
ITRM20040625A1 (it) Placca occlusiva personalizzata, per la cura di patologie posturali e relativo procedimento.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

Owner name: THE GOVERNEMENT OF THE UNITED STATES OF AMERICA

Free format text: THE GOVERNMENT OF THE UNITED STATES OF AMERICA REP BY THE SECRETARY. DEPARTMENT OF HEALTH AND HUMANSERVICES, OFFICE OF TECHNOLOGY TRANSFER NATIONAL INST OF HEALTH, 6011 EXECUTIVE BOULEVARD, SUITE 325, US-MD20852 ROCKVILLE, USA

FC2A Withdrawal, rejection or dismissal of laid open patent application